Prejuvenation: What the Evidence Says
Prejuvenation is a prevention claim made to people who have nothing to treat yet, which makes it the hardest kind of claim to test and the easiest to sell. A face with no findings has no measurable baseline, so a benefit cannot be demonstrated while the risks of treatment remain real and immediate. What is established here is short: sun protection and not smoking prevent a substantial part of what skin ageing looks like, and nothing else in the category does. Nothing is approved with a preventive indication for facial ageing, because approvals are for a change already present. This site grades the prevention claims honestly and states plainly where a claim cannot be tested at all.
Chongqing West District Hospital, a tertiary general hospital in Jiulongpo District, Chongqing. This is a review of published evidence and regulation, not medical advice, and it is not a recommendation for or against any treatment.
How claims are graded here
Every claim in this review sits in one of four groups, and in this subject the grading has to do something the other evidence reviews in this cluster do less often: it has to record that a claim cannot be tested at all, rather than merely that it has not been. Established means the claim follows from long-running evidence and needs no clinical intervention to act on — that daily sun protection prevents photoageing, and that not smoking prevents part of skin ageing, are in this group. Limited means there is evidence and it is narrower than the claim made from it, which is where treating movement lines early sits. Emerging means a signal without mature work. Not supported means the claim is made confidently and nothing carries it.
One structural problem explains most of the grading, and it is worth stating before any individual claim. A prevention claim is tested by comparing people who were treated with people who were not, over a period long enough for the prevented change to have appeared. In facial ageing that means years. The studies that exist run for months, use small groups, and measure a proxy rather than the avoided outcome. And where the person has no finding to begin with, there is no baseline against which a benefit could be shown even in principle. This is not an argument that prevention is impossible. It is a description of why the evidence in this category is so thin, and why a claim can sound reasonable and remain untestable.
Is anything approved for prevention
Nothing is approved with a preventive indication for facial ageing. Approvals in this field are for treating a change that is already present: a filler for the correction of a defined area or deficiency, a toxin product for defined muscle-related indications, a device for an endpoint such as pigment or wrinkles, and a topical for a defined skin condition and in some markets fine lines. Each of those indications describes repairing or reducing something that exists, and none describes preventing something that does not.
That has an unusual consequence for the category. In most of this cluster, a claim can be checked against an approval and found either to match or to overreach. Here, a prevention claim is asking for something the regulatory structure has no way to grant, because an avoided change is not an endpoint that can be measured in the way a treated one can. A page that cites an approval in support of a preventive benefit has borrowed a fact about treating something that exists and applied it to preventing something that does not.
What regulation does provide is a set of labelled risks for every substance and device in the category, and those apply whether or not the person has a finding. A prevention plan therefore asks a person to accept labelled risks for a benefit that no approval covers and no baseline allows to be measured. That is worth stating plainly rather than around, and it is not an argument against treating anything — it is a description of what the evidence and the labelling actually say.
What the evidence establishes
These claims survive scrutiny, and the list is short. Two of the three need nothing clinical to act on.
Daily sun protection prevents photoageing
Established, and it is the strongest preventive claim in the whole field. It is supported by long-running studies in whole populations rather than by short trials in small groups, and the mechanism is direct: reducing ultraviolet exposure reduces the accumulation of photodamage. It needs no clinical intervention, it is cheap, and its weakness is behavioural rather than scientific, because the benefit depends on daily use.
Not smoking prevents part of skin ageing
Established. Smoking is associated with earlier and more pronounced facial ageing, consistently across studies and populations, and that part of the ageing process is preventable by not smoking. It is a statement about populations rather than a prediction about an individual, and taken with sun protection it accounts for the great majority of what can honestly be called prevention in this subject.
Treating visible movement lines early limits their deepening
Limited, and precisely stated. Where a line is already visible and is produced by muscle movement, treating it reduces the movement that deepens it, and the line does not progress as it otherwise would while the treatment continues. That is preventing a change from worsening rather than preventing it from appearing, and the distinction is the whole of the claim.
Claims the evidence does not carry
These claims are common, and none of them is supported. In this subject the unsupported part of the category is nearly all of it.
That treatment before any change appears prevents ageing
Not supported, and it is the central claim of the category. There is nothing to treat, so there is no finding to record and no baseline against which a benefit could be shown. No regulator approves a preventive indication for facial ageing, and no study has compared treated and untreated people over the years that would be needed to show that a change was avoided.
That regular preventive filler keeps a face unchanged
Not supported. Filler adds volume to soft tissue where it is placed, and it does not stop the processes that reduce volume elsewhere or that change the skin. The comparison that would be needed — treated against untreated, over years, with a graded appearance — has not been made, and a face that is maintained is a face that is being treated rather than one that has stopped changing.
That early collagen stimulation prevents later laxity
Not supported. The reasoning is that stimulating collagen while the skin is healthy builds a reserve against later change. It is a plausible mechanism and it has not been demonstrated, because demonstrating it would require following treated and untreated people for long enough for laxity to develop and to be measured. No study of that kind exists for any device in this category.
That treating a face with no findings carries no risk
Not supported. Every intervention in this category carries labelled risks whether or not the person has a finding: bruising, nodules, asymmetry, infection and rarely vascular occlusion for an injectable; burn, pigment change and scarring for a device. A prevention claim asks a person to accept those risks for a benefit that cannot be measured, which is the opposite of the usual risk-benefit arrangement.
That starting younger produces a larger benefit
Not supported for anything except sun protection and not smoking. The argument is intuitive and it is not evidence: it assumes that the mechanism of the treatment interacts with age in a way nobody has measured. For sun protection and not smoking it is genuinely true, because exposure accumulates over decades and avoiding it early prevents more. For everything else in the category, the claim has not been tested.
What the risks are, stated plainly
The first risk in this subject is that treating a face with no findings carries the risks without the possibility of a measurable benefit. That is not a rhetorical point; it is the structure of the proposition. Every intervention has labelled risks, and the entire justification for accepting them in ordinary practice is that there is a finding to improve. Where there is no finding, the risk is accepted for a benefit that cannot be demonstrated, and a reader is entitled to know that before deciding anything.
The clinical risks are the labelled ones and they apply regardless of whether a finding exists. An injectable carries bruising and swelling that settle, nodules and lumps that may need treatment, asymmetry, infection and, rarely, vascular occlusion that can cause skin loss or visual loss. A device carries burn, pigment change and scarring, and pigment change is more likely in some skin types than others. Topical retinoids cause irritation and photosensitivity, particularly in the first weeks. None of those risks is reduced by the fact that the person has nothing to treat, and some of them are harder to accept when the result is invisible because there was nothing visible to change.
There are limits on the evidence, and they are more severe here than anywhere else in this cluster. A prevention claim needs a long follow-up against a comparison group, and the studies in this category run for months and measure proxies. Where the person has no finding, there is no baseline, so a benefit cannot be shown even in principle. Outcomes that depend on judging an appearance are difficult to measure consistently, and observer ratings vary. And the prevention claim has a property that makes it unusually resistant to correction: a person who has been treated and whose skin looks good years later cannot know whether the treatment caused it, and neither can anyone else, which is precisely why the claim survives without evidence.
What else is on the table, including doing nothing
The alternatives here are unusually strong, because the best-supported preventive measures need nothing clinical. Daily sun protection and not smoking are the interventions with substantial evidence behind them, they cost little, they carry almost no risk, and they can be started at any age with a benefit. A person doing those two things is doing more, in evidence terms, than a person buying a preventive treatment programme, and the comparison is not close.
Waiting is the second alternative and it is more useful than it sounds. A face with no findings is a face with no baseline, and the honest consequence is that nothing can be measured. Waiting means revisiting the question when a specific finding appears, at which point the finding can be assessed on its own terms, photographed, treated and compared. That is a better-defined proposition than treating a category, and it is available to anyone who does not act now.
Where a specific finding does appear, the options are the ones described on the device, injectable and topical guides elsewhere in this cluster, each with its own evidence position. Where the concern is sun damage that is already present, that is a treatment question rather than a prevention one. And where nothing specific can be named, doing nothing while protecting the skin is not a failure to act; it is the option with the strongest evidence behind it. Which applies is an individual clinical question, and this review does not answer it for anyone.
How this review is kept current
This subject moves on two clocks, and the gap between them is wider here than anywhere else in the cluster. The evidence moves extremely slowly, because a prevention claim about facial ageing needs years of follow-up against a comparison group and a way of grading an appearance that does not yet exist. The market moves quickly, because prevention is an appealing proposition to a younger audience and the vocabulary around it is generated by clinics rather than by journals.
This review is therefore dated and reviewed on a short cycle, and the review covers three things. The first is whether any claim has moved between the grading groups, in either direction, because a claim can become supported as well as cease to be. The second is regulatory status, since a preventive indication granted anywhere would be a significant change and an approval, a restriction or a labelling change is a checkable fact that readers are entitled to have current. The third is whether the evidence base has changed in kind: a longer follow-up of an existing study is a different event from a controlled comparison of treated and untreated people, and only the second can settle the question this site is about.
Where this review is wrong, the correction is made to the page rather than noted somewhere else, and the date of the most recent review is shown on every page. Where a claim cannot be tested, this review says that it cannot be tested rather than implying that it has failed, because those are different statements and the second would be as inaccurate as the promise. Where the evidence points to something requiring no intervention at all, this review says that too.
Prejuvenation: prevention claims, graded against what can be shown
Every row is a claim you are likely to meet, placed against what the evidence supports and what regulators have actually approved. Evidence and regulatory status are two separate columns because they answer two separate questions.
The evidence guides
Each guide answers one question about the claim rather than about a treatment. Read the two or three that match what you are trying to establish.
What Prejuvenation Means, and What It Asks You to Believe
Prevention is claimed for a change that has not happened yet, which is the hardest kind of claim to test and the easiest kind to sell.
Read the guide →Why a Prevention Claim Is So Hard to Test
A change that may or may not have occurred cannot be measured, and an unmeasurable benefit cannot be weighed against a real risk.
Read the guide →Why Prejuvenation Is Being Offered to Younger Patients
An audience with no findings is an audience with no baseline. What the shift in age changes about the advice, and what it does not.
Read the guide →Regulatory Status: Is Anything Approved for Prevention
No substance or device carries a preventive indication for facial ageing. Approvals are for treating a change that is already present.
Read the guide →What the Evidence Actually Supports About Prevention
Sun protection and not smoking, the strongest evidence in the whole field, and very little else. Neither needs a clinical treatment.
Read the guide →What Is Not Established About Prejuvenation
Early injectables, early devices and maintenance programmes, none of which has been shown to prevent anything from happening.
Read the guide →A question about the prevention evidence?
This site is an evidence review rather than a booking page, and it does not recommend for or against any treatment or offer an assessment in relation to anything it describes. If you have a question about this review, or about what the evidence does and does not cover, contact the team and ask.
Frequently asked questions
What is prejuvenation?
A prevention claim made to people who have nothing to treat yet: the proposition that treating skin before any change appears will prevent changes later. It is the hardest kind of claim to test, because a face with no findings has no baseline and a benefit cannot be measured, and it is the easiest kind to sell, because the result will not be visible for years.
Can treating young skin prevent ageing?
Not on the evidence that exists. Two preventive measures have substantial support — daily sun protection and not smoking — and neither requires a clinical treatment. Nothing else in the category has been shown to prevent a change from appearing, and the study that would show it would need treated and untreated people followed for years with a graded appearance.
Does early treatment at least do no harm?
It carries the labelled risks of whatever is used, whether or not a finding exists. Injectables carry bruising, nodules, asymmetry, infection and rarely vascular occlusion; devices carry burn, pigment change and scarring. A prevention claim asks a person to accept those risks for a benefit that cannot be measured, which is the opposite of the usual arrangement.
Is anything approved to prevent facial ageing?
No. Approvals in this field are for treating a change that is already present: a filler for a defined deficiency, a toxin product for muscle-related indications, a device for an endpoint such as pigment or wrinkles. None of those describes preventing something that does not yet exist, and no preventive indication has been granted for facial ageing.
Why is prejuvenation offered to younger patients?
Because an audience with no findings is an audience with no baseline, so nothing can be shown not to work. The advice that survives scrutiny is worth starting early — sun protection and not smoking do the most good when begun young — and that sound instinct is used to support treatments for which no preventive evidence exists.
What actually has evidence behind it for prevention?
Daily sun protection, by a distance, and not smoking. Both are supported by long-running population studies, both cost little, and neither needs a clinical intervention. Limiting the deepening of a movement line that is already visible is supported to a lesser degree, and it is preventing a change from worsening rather than preventing one from appearing.
Part of Sun Damage and Ageing Skin — 8 sites on this topic